Europe Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

The Europe human microbiome market size is expected to reach US$ 999.66 million by 2031 from US$ 204.79 million in 2023. The market is estimated to record a CAGR of 21.9% from 2023 to 2031.

Executive Summary and Europe Human Microbiome Market Analysis:

The Europe human microbiome market is segmented into France, Germany, the UK, and the Rest of Europe. Europe occupies a significant position in the global human microbiome market and is expected to register a robust growth rate during 2023–2031. The rising number of ongoing studies on the human microbiome and the increase in the prevalence of chronic diseases and disorders are further fueling the growth of the human microbiome market. Also, an increase in various research programs for human microbiomes is likely to be the major factor driving the growth of this market in Europe.

Europe Human Microbiome Market Strategic Insights

Get more information on this report Request Free Sample PDF

Europe Human Microbiome Market Segmentation Analysis

Key segments that contributed to the derivation of the Europe human microbiome market analysis are type, application, and disease type.

• Based on type, the Europe human microbiome market is bifurcated into product and software and services. The product held a larger share of the market in 2023.The product segment is further sub segmented into probiotics and prebiotics.
• Based on application, the Europe human microbiome market is segmented into therapeutics, diagnostics, and research. The therapeutics held the largest share of the market in 2023.
• Based on disease type, the Europe human microbiome market is segmented into obesity, diabetes, autoimmune disorder, cancer, GIT, and others. The GIT held the largest share of the market in 2023.

Europe Human Microbiome Market Outlook

The human microbiome industry's growth, innovation, and market dynamics are greatly influenced by the investments made by major players in the market. Major players are engaged in making significant investments in research and development to create novel probiotics, diagnostics, and treatments based on the microbiome. These expenditures stimulate innovation, identifying new strains, modes of action, and medicinal uses. Clinical trials receive a large amount of funding, which is essential for demonstrating the effectiveness and safety of products based on the microbiome. A pioneer in microbiome mapping technology, Kanvas Biosciences, announced a US$ 12 million Pre-Series A funding round in June 2023. The company's proprietary platform technology, which has the potential to transform drug development for illnesses linked to the microbiome, will be further developed with the help of the investment. These partnerships make sharing resources, know-how, and technological advancements easier, speeding up product development. For instance, a new collaboration was announced between the world's largest food and beverage company, Nestlé, and a top-tier SFI research center, APC Microbiome Ireland, in July 2023. The collaboration centers on different aspects of the human microbiome and helps develop new products to enhance human health and wellness. As many as 120 companies are reportedly investing in microbiome analysis, and numerous startups are entering this field. Flagship Pioneering, Seventure Partners, and BioGaia are the most active investors. Thus, increase in investments by key players is likely drive the growth of market.

Europe Human Microbiome Market Country Insights

Based on country, the Europe human microbiome market comprises the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany held the largest share in 2023.

Germany is considered a major hub for biotechnological research in Europe and across the world, owing to the presence of large biotechnology players, high-tech research labs, and massive funding for the conduction of research and development. The ongoing research and development activities and changing government regulations to favor microbiome therapeutics development in the country create lucrative opportunities. In 2022, Vagisan ProbioFlora, manufactured by Dr. Wolff Group, was reclassified and obtained medicinal product status. The positive impact of these developments extends beyond probiotics, promoting innovation and benefiting the broader microbiome-driven pharmaceutical industry as well.

Market players are investing heavily in research and development activities in the human microbiome market in Germany. For instance, in March 2023, mbiomics GmbH announced a successful first closing of its series A financing round, raising EUR 13 million (US$ 15 million). MIG Capital led the round, with participation from High-Tech Gründerfonds, Bayern Kapital, and private seed investors. mbiomics uses its proprietary high-resolution profiling platform and computational techniques to design more effective microbial consortia for precision therapies and to enhance patient selection and monitoring for clinical trials.

Europe Human Microbiome Market Report Highlights

Europe Human Microbiome Market Company Profiles

Some of the key players operating in the market MaaT Pharma; Ferring Holdings SA; AOBiome Therapeutics Inc; Finch Therapeutics Group Inc; Seres Therapeutics Inc; Merck & Co Inc; Rebiotix, Inc.; Yakult Honsha Co., Ltd.; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Human Microbiome Market Research Methodology :

The following methodology has been followed for the collection and analysis of data presented in this report:

• Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.
• Industry trade journals and other relevant publications.
• Government documents, statistical databases, and market reports.
• News articles, press releases, and webcasts specific to companies operating in the market.

Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

• Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.
• Enhance the expertise and market understanding of the analysis team.
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise

Europe Human Microbiome Market Country and Regional Insights